Literature DB >> 24502405

Herpes simplex viral vectors: late bloomers with big potential.

Joseph C Glorioso1.   

Abstract

Mesh：

Year:  2014        PMID： 24502405      PMCID： PMC3922308          DOI： 10.1089/hum.2014.2501

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  42 in total

1.  Efficient activation of viral genomes by levels of herpes simplex virus ICP0 insufficient to affect cellular gene expression or cell survival.

Authors:  W E Hobbs; D E Brough; I Kovesdi; N A DeLuca
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 2.  Herpes simplex virus type 1-based amplicon vector systems.

Authors:  C Fraefel; D R Jacoby; X O Breakefield
Journal:  Adv Virus Res       Date:  2000       Impact factor: 9.937

3.  Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion.

Authors:  J R Goss; M Mata; W F Goins; H H Wu; J C Glorioso; D J Fink
Journal:  Gene Ther       Date:  2001-04       Impact factor: 5.250

4.  Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain.

Authors:  Shuanglin Hao; Marina Mata; William Goins; Joseph C Glorioso; David J Fink
Journal:  Pain       Date:  2003-03       Impact factor: 6.961

5.  Connexin 43-enhanced suicide gene therapy using herpesviral vectors.

Authors:  P Marconi; M Tamura; S Moriuchi; D M Krisky; A Niranjan; W F Goins; J B Cohen; J C Glorioso
Journal:  Mol Ther       Date:  2000-01       Impact factor: 11.454

Review 6.  Gene therapy for chronic pain.

Authors:  Joseph C Glorioso; Marina Mata; David J Fink
Journal:  Curr Opin Mol Ther       Date:  2003-10

7.  Improved packaging system for generation of high-level noncytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes.

Authors:  Cécile Zaupa; Valerie Revol-Guyot; Alberto L Epstein
Journal:  Hum Gene Ther       Date:  2003-07-20       Impact factor: 5.695

8.  Herpes vector-mediated expression of proenkephalin reduces bone cancer pain.

Authors:  James R Goss; Cara F Harley; Marina Mata; Mark E O'Malley; William F Goins; XiaoPing Hu; Joseph C Glorioso; David J Fink
Journal:  Ann Neurol       Date:  2002-11       Impact factor: 10.422

Review 9.  Progress in gene therapy for neurological disorders.

Authors:  Michele Simonato; Jean Bennett; Nicholas M Boulis; Maria G Castro; David J Fink; William F Goins; Steven J Gray; Pedro R Lowenstein; Luk H Vandenberghe; Thomas J Wilson; John H Wolfe; Joseph C Glorioso
Journal:  Nat Rev Neurol       Date:  2013-04-23       Impact factor: 42.937

Review 10.  Oncolytic viruses as therapeutic cancer vaccines.

Authors:  David L Bartlett; Zuqiang Liu; Magesh Sathaiah; Roshni Ravindranathan; Zongbi Guo; Yukai He; Zong Sheng Guo
Journal:  Mol Cancer       Date:  2013-09-11       Impact factor: 27.401
View more
  9 in total

Review 1.  Virotherapy: cancer gene therapy at last?

Authors:  Alan E Bilsland; Pavlina Spiliopoulou; T R Jeffry Evans
Journal:  F1000Res       Date:  2016-08-30

2.  Viral Vector Biosafety in Laboratory Animal Research.

Authors:  Dalis E Collins; Jon D Reuter; Howard G Rush; Jason S Villano
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

Review 3.  Current Trends in Viral Gene Therapy for Human Orthopaedic Regenerative Medicine.

Authors:  Jagadeesh Kumar Venkatesan; Ana Rey-Rico; Magali Cucchiarini
Journal:  Tissue Eng Regen Med       Date:  2019-02-21       Impact factor: 4.169

4.  Efficacy of Herpes Simplex Virus Vector Encoding the Human Preproenkephalin Gene for Treatment of Facial Pain in Mice.

Authors:  Fei Ma; Chunmei Wang; William E Yoder; Karin N Westlund; Charles R Carlson; Craig S Miller; Robert J Danaher
Journal:  J Oral Facial Pain Headache       Date:  2016

5.  Gene Transfer of Brain-derived Neurotrophic Factor (BDNF) Prevents Neurodegeneration Triggered by FXN Deficiency.

Authors:  Yurika Katsu-Jiménez; Frida Loría; Juan Carlos Corona; Javier Díaz-Nido
Journal:  Mol Ther       Date:  2016-02-05       Impact factor: 11.454

6.  Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.

Authors:  Timothy P Cripe; Chun-Yu Chen; Nicholas L Denton; Kellie B Haworth; Brian Hutzen; Jennifer L Leddon; Keri A Streby; Pin-Yi Wang; James M Markert; Alicia M Waters; George Yancey Gillespie; Elizabeth A Beierle; Gregory K Friedman
Journal:  Mol Ther Oncolytics       Date:  2015-09-16       Impact factor: 7.200

7.  DNA vaccination for prostate cancer: key concepts and considerations.

Authors:  Grace Cole; Joanne McCaffrey; Ahlam A Ali; Helen O McCarthy
Journal:  Cancer Nanotechnol       Date:  2015-07-02

8.  Improvement of HSV-1 based amplicon vectors for a safe and long-lasting gene therapy in non-replicating cells.

Authors:  Marie Soukupová; Silvia Zucchini; Pascal Trempat; Selene Ingusci; Coline Perrier-Biollay; Mario Barbieri; Stefano Cattaneo; Barbara Bettegazzi; Simonetta Falzoni; Hervé Berthommé; Michele Simonato
Journal:  Mol Ther Methods Clin Dev       Date:  2021-03-29       Impact factor: 6.698

Review 9.  Oncolytic virotherapy for pediatric malignancies: future prospects.

Authors:  Alicia M Waters; Gregory K Friedman; Eric K Ring; Elizabeth A Beierle
Journal:  Oncolytic Virother       Date:  2016-08-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.